Determinants of compliance to influenza and COVID-19 vaccination in a cohort of solid organ transplant patients in Puglia, Southern Italy (2017

Determinants of compliance to influenza and COVID-19 vaccination in a cohort of solid organ transplant patients in Puglia, Southern Italy (2017–2022)

Published:2023-10-16 Issue:3 Volume:19 Page:
ISSN:2164-5515
Container-title:Human Vaccines & Immunotherapeutics
language:en
Short-container-title:Human Vaccines & Immunotherapeutics

Author:

Stefanizzi Pasquale¹,Bianchi Francesco Paolo¹,Moscara Lorenza¹,Martinelli Andrea¹,Di Lorenzo Antonio¹,Gesualdo Loreto²,Simone Simona²,Rendina Maria³,Tafuri Silvio¹^ORCID

Affiliation:

1. Hygiene Unit – Interdisciplinary Department of Medicine, University of Bari Aldo Moro, Bari, Italy

2. Nephrology, Dialysis and Transplantation Unit, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari Aldo Moro, Bari, Italy

3. Section of Gastroenterology, Department of Emergency and Organ Transplantation, University of Bari, Bari, Italy

Funder

no funding

Publisher

Informa UK Limited

Subject

Pharmacology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/21645515.2023.2266932

Reference53 articles.

1. Viral Respiratory Tract Infections in Transplant Patients

2. Respiratory Viral Infections in Hematopoietic Stem Cell and Solid Organ Transplant Recipients

3. Burden, epidemiology, and outcomes of microbiologically confirmed respiratory viral infections in solid organ transplant recipients: a nationwide, multi‐season prospective cohort study

4. Influenza in Solid Organ Transplant Recipients

5. Clinical outcome in solid organ transplant recipients affected by COVID-19 compared to general population: a systematic review and meta-analysis

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness of COVID-19 vaccines against severe outcomes in cancer patients: Real-world evidence from self-controlled risk interval and retrospective cohort studies;Journal of Infection and Public Health;2024-05

2. Safety profile of recombinant adjuvanted anti-herpes zoster vaccine (RZV) in high-risk groups: Data from active surveillance program. Puglia (Italy), 2021–23;Vaccine;2024-04